Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

ABSTRACT Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lisa K. McNeil, Robert G. K. Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L. Harris, Thomas R. Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A. Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A. Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W. Mayer, Michael W. Pride, Kathrin U. Jansen, Annaliesa S. Anderson
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2018
Materias:
meningococcal antigen surface expression (MEASURE) assay
Neisseria meningitidis serogroup B
factor H binding protein
flow cytometry
vaccine
Microbiology
QR1-502
Acceso en línea:https://doaj.org/article/c3d0bb482f1f4b6d8d47c0ace63109e3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares